stock clariti
lack clariti potenti isr suppli surpris investor
highlight earn note disclos fewer
pump avail initi isr launch unabl
manufactur addit pump fda approv next-gener
system anticip late may take longer given
expect fda action date juli manag recent
bullish program investor taken surpris consid
potenti impact disclosur manag directli address
possibl short-term suppli problem call commentari suggest
continu see lt potenti isr manag
remain confid approv work commerci launch
earli
pipelin develop compani disclos accumul
enough event meet requir clinic worsen event
unblind freedom-ev event current adjud full
result studi expect compani also highlight
expect file ind remopro pain-fre sc treprostinil prodrug later
year see substanti opportun product signific de-
risk still requir limit detail product disclos
valuationreiter neutral lower tp
adjust revenu project reflect lower estim isr
decreas expens project in-lin actual
take ep upsid risk includ resist
gener uptak unexpect pipelin develop product/pipelin
acquisit downsid risk incl greater vulner tyvaso gener
failur isr gain approv
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
mariu zoican univers toronto rotman school manag may
unit therapeut corpor biotechnolog compani
focus develop commerci product
treatment chronic life-threaten condit
price may rate neutral target price analyst martin auster
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
upsid case assum gener obtain parenter
treprostinil share compound-annual-growth-rate annual
growth tyvaso annual growth orenitram
follow success freedom-ev clinic trial
downsid case assum gener obtain parenter
treprostinil share compound-annual-growth-rate remodulin franchis
gradual share loss tyvaso gener enter
market compound-annual-growth-rate clinic failur
freedom-ev result compound-annual-growth-rate
 close
mariu zoican univers toronto rotman school manag figur model chang
million except ep
mariu zoican univers toronto rotman school manag may
compani mention price
